Foghorn Therapeutics Inc. Variable Lease, Cost
Foghorn Therapeutics Inc. (FHTX) reported Variable Lease, Cost of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-06
- Foghorn Therapeutics Inc. variable lease, cost for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Foghorn Therapeutics Inc. variable lease, cost for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Foghorn Therapeutics Inc. variable lease, cost for the quarter ending 2025-12-31 was $529.00K, a 24.10% decline year-over-year.
- Foghorn Therapeutics Inc. variable lease, cost for the quarter ending 2025-09-30 was $619.00K, a 18.34% decline year-over-year.
- Foghorn Therapeutics Inc. variable lease, cost for fiscal 2025 was $2.65M, a 13.06% decline from fiscal 2024.
- Foghorn Therapeutics Inc. variable lease, cost for fiscal 2024 was $3.05M, a 10.85% increase from fiscal 2023.
- Foghorn Therapeutics Inc. variable lease, cost for fiscal 2023 was $2.75M, a 17.09% decline from fiscal 2022.
- Foghorn Therapeutics Inc. variable lease, cost for fiscal 2022 was $3.32M, a 14.90% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $529.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $529.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.15M derived: sum of 3 quarters · filed 2026-05-07 | $1.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $529.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $1.15M derived: sum of 2 quarters · filed 2026-03-11 | $1.85M derived: sum of 3 quarters · filed 2026-08-06 | $2.65M 10-K · filed 2026-03-11 |
| 2025-09-30 | $619.00K 10-Q · filed 2025-11-05 | $1.32M derived: sum of 2 quarters · filed 2026-08-06 | $2.13M 10-Q · filed 2025-11-05 | $2.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $699.00K 10-Q · filed 2026-08-06 | $1.51M 10-Q · filed 2026-08-06 | $2.21M derived: sum of 3 quarters · filed 2026-08-06 | $2.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $809.00K 10-Q · filed 2026-05-07 | $1.51M derived: sum of 2 quarters · filed 2026-05-07 | $2.26M derived: sum of 3 quarters · filed 2026-05-07 | $3.04M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $697.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $1.46M derived: sum of 2 quarters · filed 2026-03-11 | $2.23M derived: sum of 3 quarters · filed 2026-03-11 | $3.05M 10-K · filed 2026-03-11 |
| 2024-09-30 | $758.00K 10-Q · filed 2025-11-05 | $1.53M derived: sum of 2 quarters · filed 2025-11-05 | $2.36M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $771.00K 10-Q · filed 2025-08-05 | $1.60M 10-Q · filed 2025-08-05 | ||
| 2023-12-31 | $2.75M 10-K · filed 2025-03-06 | |||
| 2022-12-31 | $3.32M 10-K · filed 2024-03-07 | |||
| 2021-12-31 | $670.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $1.40M derived: sum of 2 quarters · filed 2023-03-09 | $2.13M derived: sum of 3 quarters · filed 2023-03-09 | $2.89M 10-K · filed 2023-03-09 |
| 2021-09-30 | $731.00K 10-Q · filed 2021-11-09 | $1.46M derived: sum of 2 quarters · filed 2021-11-09 | $2.22M 10-Q · filed 2021-11-09 | $2.82M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-06-30 | $727.00K 10-Q · filed 2021-08-10 | $1.49M 10-Q · filed 2021-08-10 | $2.09M derived: sum of 3 quarters · filed 2022-08-09 | $2.31M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $763.00K 10-Q · filed 2021-05-11 | $1.36M derived: sum of 2 quarters · filed 2022-08-09 | $1.59M derived: sum of 3 quarters · filed 2022-08-09 | $1.74M derived: sum of 4 quarters · filed 2022-08-09 |
| 2020-12-31 | $600.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-08-09 | $825.00K derived: sum of 2 quarters · filed 2022-08-09 | $981.00K derived: sum of 3 quarters · filed 2022-08-09 | $1.22M 10-K/A · filed 2022-08-09 |
| 2020-09-30 | $225.00K 10-Q · filed 2021-11-09 | $381.00K derived: sum of 2 quarters · filed 2021-11-09 | $617.00K 10-Q · filed 2021-11-09 | $816.00K derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $156.00K 10-Q · filed 2021-08-10 | $392.00K 10-Q · filed 2021-08-10 | $591.00K derived: sum of 3 quarters · filed 2021-08-10 | $701.00K derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $236.00K 10-Q · filed 2021-05-11 | $435.00K derived: sum of 2 quarters · filed 2021-05-11 | $545.00K derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $199.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $309.00K derived: sum of 2 quarters · filed 2021-03-18 | $547.00K 10-K · filed 2021-03-18 | |
| 2019-09-30 | $110.00K 10-Q · filed 2020-12-04 | $348.00K 10-Q · filed 2020-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |